
















For	 humans,	 eating	 control	 is	 crucial.	 When	 metabolic	 homeostasis	 can	 be	 maintained,	 feeding	 function	
involves	the	hypothalamus	and	brain	stem.	When	food	intake	exceeds	metabolic	homeostasis,	reward	system	
is	 involved	such	as	dopamine	neurons	 from	the	ventral	 tegmental	area,	 the	nucleus	accumbens,	and	 limbic	
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Recently,	 metabolic	 syndrome	 (Met-S),	 diabetes	 and	 obesity	 have	 been	more	 prevalent	 internationally.	 In	



















































They	 are	 i)	 exenatide	 subcutaneously	 injected	 twice	 daily,	 ii)	 lixisenatide	 and	 liraglutide	 subcutaneously	
injected	once	daily,	iii)	exenatide,	duraglutide	and	semaglutide	once	weekly	subcutaneously	injected,	iv)	oral	
type	of	semaglutide,	which	was	examined	in	the	PIONEER	study.	Then,	the	same	or	better	hypoglycemic	effect	












A	 68-week	 intervention	 was	 performed.	 As	 a	 result,	 a	 14.9%	 (15.3	 kg)	 reduction	 was	 achieved	 in	 the	
semaglutide-administered	group.	This	was	 found	to	have	a	 large	effect	similar	 to	 that	of	weight	reduction/	
metabolism	 improvement	 surgery	 [16].	 The	 average	 weight	 reduction	 in	 the	 placebo	 group	 was	 2.6	 kg.	
Temporary	 nausea	 and	 diarrhea	 were	 observed	 in	 40%	 of	 the	 semaglutide	 group,	 of	 which	 7%	 in	 the	
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